Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation

Betul Oran, Peter Thall, Jeremy Ramdial et al. Nov 03, 2025 pp. 2515-2515 10.1182/blood-2025-2515

Abstract Background: Allogeneic stem cell transplantation (alloSCT) remains the only potentially curative therapy for patients with acute ly...

Lung infections and clinical outcomes of diffuse large B-cell lymphoma treated with polatuzumab vedotin-based combination therapy

Ning Wang, Feili Chen, Zetao Chen et al. Nov 03, 2025 pp. 8090-8090 10.1182/blood-2025-8090

Abstract Background: Real-world clinical data on the polatuzumab vedotin-based regimen for the treatment of diffuse large B-cell lymphoma (D...

Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study

Lizhen Liu, Shipei Xiang, Xiaoyu Lai et al. Nov 03, 2025 pp. 1061-1061 10.1182/blood-2025-1061

Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the only cure for acute myeloid leukemia...

Comparative effectiveness of second-line therapies for chronic immune thrombocytopenia: A network meta-analysis of RCTs

Rakhshanda khan, Anusha Kalluru, Harshawardhan Dhanraj Ramteke et al. Nov 03, 2025 pp. 6592-6592 10.1182/blood-2025-6592

Abstract Introduction: Chronic immune thrombocytopenia (ITP) is characterized by low platelet counts, increasing the risk of bleeding. While...

Descriptive analysis of IgM monoclonal gammopathy of undetermined significance progression events in US veterans

Lawrence Liu, Byron Sigel, Mei Wang et al. Nov 03, 2025 pp. 5750-5750 10.1182/blood-2025-5750

Abstract Background: Immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (IgM) is rare making up 15% MGUS but carries...

CLL bone marrow infiltration is associated with osteocyte loss and adipose tissue fragmentation: A high-resolution imaging study

In Kyu Lee, Yoshihiro Obata, Anthony Pomicter et al. Nov 03, 2025 pp. 3179-3179 10.1182/blood-2025-3179

Abstract Axial fragility fractures are about 60% more common in chronic lymphocytic leukemia (CLL) than in age-matched peers, even when dual...

Transition of care of youth with bone marrow failure conditions: Current practices, barriers, and burden- a survey of hematology-oncology providers in the US.

Cameron Perry, Irem Eldem, Sara Zarnegar-Lumley et al. Nov 03, 2025 pp. 4394-4394 10.1182/blood-2025-4394

Abstract Introduction: Adolescents and young adults (AYA) with bone marrow failure (BMF) experience illness at a time wh...

Improved outcome of patients with acute myeloid leukemia treated by a dedicated leukemia service in a community hospital

Maria Sbenghe, Margaret Schuyler, Julia Wuest et al. Nov 03, 2025 pp. 6204-6204 10.1182/blood-2025-6204

Abstract Introduction Acute Myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest numbe...

Development and validation of a risk assessment model for inpatient venous thrombosis in people with cancer

Karlyn Martin, Katherine Wilkinson, Andrew Sparks et al. Nov 03, 2025 pp. 20-20 10.1182/blood-2025-20

Abstract Introduction Venous thromboembolism (VTE) acquired during hospitalization (hospital-acquired VTE) causes increa...

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Bruno Fattizzo, Henrik Frederiksen, Alessandro Lucchesi et al. Nov 03, 2025 pp. 4655-4655 10.1182/blood-2025-4655

Abstract Introduction: wAIHA is a rare type of anemia caused by destruction of red blood cells (RBCs) mostly due to IgG (warm antibody) bind...

Genomic profiling identifies somatic alterations predicting thromboembolic risk in patients with lymphoma

Varun Iyengar, Zachary Epstein-Peterson, Andriy Derkach et al. Nov 03, 2025 pp. 19-19 10.1182/blood-2025-19

Abstract Introduction Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. VTE rates vary sig...

Long-term follow-up results of nonremission relapsed/refractory DLBCL with CAR T-cell cocktail therapy alone or in combination with ASCT

Xiaoying Zhang, Jue Wang, Na Wang et al. Nov 03, 2025 pp. 7243-7243 10.1182/blood-2025-7243

Abstract Objective: Chimeric antigen receptor T-cell (CAR-T) significantly improve clinical outcomes in relapsed/refractory diffuse large B-...

Single-cell multi-omics uncovers differentiation-dependent transcriptional programs shaping epigenetic subgroups in AML

Yotaro Ochi, Markus Liew-Littorin, Yasuhito Nannya et al. Nov 03, 2025 pp. 5005-5005 10.1182/blood-2025-5005

Abstract Background Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease. While traditional classification sys...

Molecular characterization of pediatric acute myeloid leukemia treated under the NOPHO-DBH-2012 protocol in the Netherlands

Elizabeth Schweighart, Maaike Luesink, Milad Rasouli et al. Nov 03, 2025 pp. 445-445 10.1182/blood-2025-445

Abstract With chemotherapy intensification reaching its limits for pediatric acute myeloid leukemia (pAML), reflected by a ~5% mortality rat...

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

Anna de Daniel, Joan Mañé Pujol, M Carmen Salgado et al. Nov 03, 2025 pp. 3983-3983 10.1182/blood-2025-3983

Abstract Background ARI0002h (cesnicabtagene autoleucel) is a second-generation humanized BCMA-directed chimeric antigen receptor (CAR) T-cel...

Complement activation profile in primary immune thrombocytopenia: Its association with PA-IgM, increased platelet turnover and clinical outcomes

Keiichi Nakata, Ichio Onami, Hisashi Kato et al. Nov 03, 2025 pp. 1268-1268 10.1182/blood-2025-1268

Abstract Background: Complement activation in primary immune thrombocytopenia (ITP) has been reported, but its clinical...

Patient-reported outcome subgroups and associated determinants in hematologic malignancies: A latent profile analysis

Yujie Zhao, Qianqian Zhang, Jinying Zhao et al. Nov 03, 2025 pp. 8156-8156 10.1182/blood-2025-8156

Abstract Aims: To identify latent profiles of patient-reported outcomes in individuals with hematologic malignancies and explore their assoc...

Left atrial reservoir strain as a novel echocardiographic marker of diastolic dysfunction and mortality risk in sickle cell cardiomyopathy

Zineb Sadraoui, Sihem Iles, Lara Alassaad et al. Nov 03, 2025 pp. 296-296 10.1182/blood-2025-296

Abstract Background: Cardiac involvement is a leading contributor to premature mortality in sickle cell disease (SCD), yet the diagnosis of...

Measuring minimal residual AML in remission using a novel multi DNA mutation based next generation sequencing assay

Darren King, Karan Bedi, Kerby Shedden et al. Nov 03, 2025 pp. 5292-5292 10.1182/blood-2025-5292

Abstract Introduction: Despite achievement of complete remission (CR) following chemotherapy, Acute Myelogenous Leukemia (AML) relapses in t...

Acute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): Real-world outcomes in the new AML treatment era

Jan Philipp Bewersdorf, Rong Wang, Lourdes Mendez et al. Nov 03, 2025 pp. 721-721 10.1182/blood-2025-721

Abstract MPNs have a variable risk of progression to AML. With a median overall survival (OS) of 3-6 months (ms), patients (pts) with post-M...

Hematopoietic stem cell transplantation using briquilimab (Anti-CD117 Antibody-Conditioning), immunosuppression and TCRαβ+ T-cell/CD19+ B-cell depleted haploidentical grafts in patients with fanconi anemia: An approach without irradiation, busulfan and calcineurin inhibitors.

Rajni Agarwal, Alice Bertaina, Charmaine Soco et al. Nov 03, 2025 pp. 2432-2432 10.1182/blood-2025-2432

Abstract Introduction: Fanconi anemia (FA) is a genetic disorder that leads to DNA repair defect and is clinically characterized by progress...

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Tony Zhuang, Xiaowen Sun, Lei Feng et al. Nov 03, 2025 pp. 5384-5384 10.1182/blood-2025-5384

Abstract Introduction: Lenalidomide in combination with anti-CD20 monoclonal antibody is a standard second line treatment for relapsed/refra...

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Arjun Raj Rajanna, Jorge Arturo Hurtado Martinez, Michael Durante et al. Nov 03, 2025 pp. 4008-4008 10.1182/blood-2025-4008

Abstract Background: We previously established the first individualized risk prediction model (IRMMa) integrating genomic, clinical, and trea...

ER-resident chaperon protein disulfide isomerase PDIA1 inhibition restricts and eliminate aberrant plasma cells

Raziullah Khan, Anand Tiwari, Mamta Sumi et al. Nov 03, 2025 pp. 7488-7488 10.1182/blood-2025-7488

Abstract One of the major hallmarks of plasma cell dyscrasias (PCDs) is dysregulated proteostasis. PCDs are a group of heterogeneous disease...

Real-world comparative effectiveness of quadruplet vs triplet induction in multiple myeloma

Nandhini Iyer, Safa Afridi, Anuja Abhyankar Nov 03, 2025 pp. 4592-4592 10.1182/blood-2025-4592

Abstract Background: The incorporation of anti-CD38 monoclonal antibodies such as Daratumumab into induction therapy has transformed the tre...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page